Insider Transactions in Q1 2021 at Epizyme, Inc. (EPZM)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2021
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,727
+1.74%
|
$21,816
$8.71 P/Share
|
|
Mar 31
2021
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,723
+13.25%
|
$13,784
$8.71 P/Share
|
|
Mar 26
2021
|
David M Mott Director |
BUY
Open market or private purchase
|
Direct |
34,486
+9.34%
|
$241,402
$7.89 P/Share
|
|
Mar 25
2021
|
Robert B Bazemore President & CEO |
SELL
Open market or private sale
|
Direct |
10,328
-3.1%
|
$72,296
$7.85 P/Share
|
|
Mar 25
2021
|
David M Mott Director |
BUY
Open market or private purchase
|
Direct |
28,231
+19.52%
|
$197,617
$7.98 P/Share
|
|
Feb 04
2021
|
Victoria Vakiener Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
817
-1.53%
|
$8,987
$11.21 P/Share
|
|
Feb 04
2021
|
Matthew Ros Officer |
SELL
Open market or private sale
|
Direct |
894
-1.06%
|
$9,834
$11.21 P/Share
|
|
Feb 04
2021
|
Joseph Beaulieu Officer |
SELL
Open market or private sale
|
Direct |
227
-1.66%
|
$2,497
$11.21 P/Share
|
|
Feb 04
2021
|
Paolo Tombesi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,021
-1.87%
|
$11,231
$11.21 P/Share
|
|
Feb 04
2021
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
969
-0.92%
|
$10,659
$11.21 P/Share
|
|
Feb 04
2021
|
Robert B Bazemore President & CEO |
SELL
Open market or private sale
|
Direct |
3,890
-1.16%
|
$42,790
$11.21 P/Share
|
|
Feb 01
2021
|
Jeffery Kutok Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,645
+33.82%
|
-
|
|
Feb 01
2021
|
Matthew Ros Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,125
+25.07%
|
-
|
|
Feb 01
2021
|
Victoria Vakiener Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,520
+32.29%
|
-
|
|
Feb 01
2021
|
Paolo Tombesi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,041
+32.34%
|
-
|
|
Feb 01
2021
|
Joseph Beaulieu Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,700
+36.05%
|
-
|
|
Feb 01
2021
|
Robert B Bazemore President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+20.67%
|
-
|
|
Feb 01
2021
|
Shefali Agarwal |
BUY
Grant, award, or other acquisition
|
Direct |
29,583
+21.93%
|
-
|
|
Jan 25
2021
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
2,872
-3.65%
|
$31,592
$11.41 P/Share
|
|
Jan 25
2021
|
Victoria Vakiener Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
599
-2.1%
|
$6,589
$11.41 P/Share
|
|
Jan 25
2021
|
Matthew Ros Officer |
SELL
Open market or private sale
|
Direct |
2,872
-4.88%
|
$31,592
$11.41 P/Share
|
|
Jan 25
2021
|
Robert B Bazemore President & CEO |
SELL
Open market or private sale
|
Direct |
6,069
-2.39%
|
$66,759
$11.41 P/Share
|